



EMBARGOED TUESDAY, OCTOBER 11, 2022

Lilly ANZ announces incoming GM

Eli Lilly (Lilly) has today announced changes to their ANZ leadership team with Benjamin Basil, President of North Asia-Pacific and General Manager of Australia and New Zealand soon to assume a new role as the President and General Manager of Eli Lilly China. Tori Brown, General Manager of Eli Lilly Switzerland will succeed Benjamin who has successfully led the NAPAC Hub over the last three-and-a-half years. These changes are expected to be effective from January 1, 2023, pending work authorisation.

Over the last seventeen years Tori has held various commercial marketing and sales roles with Lilly in the United States, Puerto Rico and most recently Switzerland. She is known for passionately cultivating high energy diverse teams that relentlessly pursue exceptional outcomes for patients.

“I am honoured to be joining the Lilly North Asia Pacific Hub, meeting the incredible people of Australia and accelerating the work we do for patients. Our robust pipeline makes this an exciting time for Lilly as we continue our pursuit for the next great discovery and for even more ways to make life better for people around the world,” said Ms. Brown.

“As I move into the role, I’m eager to get to know my Eli Lilly teammates and to learn about the culture, the healthcare system and the business in Australia and New Zealand. My goal is to ensure we’re doing our part to make an impact not only on the patients who benefit from our medicines, but also on society as a whole,” Ms. Brown said.

Tori holds a bachelor’s degree in civil engineering from Purdue University and an MBA from University of Minnesota.

Under Benjamin’s leadership Lilly ANZ has seen significant sales revenue growth and has been externally recognised two years running as an Excellence Awardee in the prestigious annual Australian HR Awards, for building a diverse and winning team culture and championing Diversity, Equity and Inclusion (DEI). In addition, Benjamin successfully led the company through the challenges and uncertainty of the COVID-19 pandemic.

Speaking on Tori’s appointment Benjamin said, “Tori is an accomplished, commercially-minded leader who cares deeply about people and puts patients at the centre of every decision.”

“Tori is committed to coaching and developing people beyond their own potential, and I am looking forward to seeing the Lilly ANZ team continuing to grow and deliver for our patients under her leadership,” said Mr. Basil.

Benjamin will succeed Julio Gay-Ger as the President and General Manager of China and will continue to sit on the Lilly International Leadership Team.

ends#



Media enquiries

Sophie Mizzi, Senior Associate, Corporate and External Affairs, Eli Lilly ANZ
0409 427 726 | mizzi_sophie@lilly.com

Lisa Julian, Associate Director, Corporate and External Affairs, Eli Lilly ANZ & NAPAC
0408 498 289 | julian_lisa@lilly.com

About Lilly

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteering. Since its founding, Lilly has pioneered major breakthroughs like insulin and the polio vaccine and has worked to make sure these discoveries reach the people around the world who need them most. For more information, visit: www.lilly.com.au.

Eli Lilly Australia Pty Limited 112 Wharf Rd, West Ryde NSW 2114, Australia. ABN 39 000233 922. PP-MG-AU-0161. Date of preparation: October 2022